Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

539 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy.
Araki T, Tateishi K, Komatsu M, Sonehara K, Wasamoto S, Koyama S, Yoshiike F, Hama M, Nishie K, Kondo D, Agatsuma T, Kato A, Takata M, Kanda S, Hanaoka M, Koizumi T. Araki T, et al. Among authors: hanaoka m. Thorac Cancer. 2022 Jul;13(14):2031-2040. doi: 10.1111/1759-7714.14484. Epub 2022 May 26. Thorac Cancer. 2022. PMID: 35616056 Free PMC article.
Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study.
Wada Y, Koyama S, Kuraishi H, Miyahara T, Yoshiike F, Agatsuma T, Yamamoto R, Ono Y, Suzuki T, Hachiya T, Gomi D, Tateishi K, Hanaoka M, Koizumi T. Wada Y, et al. Among authors: hanaoka m. Respir Investig. 2016 Nov;54(6):462-467. doi: 10.1016/j.resinv.2016.07.003. Epub 2016 Aug 25. Respir Investig. 2016. PMID: 27886858
Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group.
Sonehara K, Kobayashi T, Tateishi K, Morozumi N, Yoshiike F, Hachiya T, Ono Y, Takasuna K, Agatsuma T, Masubuchi T, Matsuo A, Tanaka H, Morikawa A, Hanaoka M, Koizumi T. Sonehara K, et al. Among authors: hanaoka m. Thorac Cancer. 2019 May;10(5):1078-1085. doi: 10.1111/1759-7714.13047. Epub 2019 Apr 20. Thorac Cancer. 2019. PMID: 31006178 Free PMC article.
The efficacy of amrubicin third-line chemotherapy in patients with relapsed extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute.
Sonehara K, Tateishi K, Fukushima T, Komatsu M, Yamamoto H, Koizumi T, Hanaoka M. Sonehara K, et al. Among authors: hanaoka m. Thorac Cancer. 2019 Sep;10(9):1805-1811. doi: 10.1111/1759-7714.13150. Epub 2019 Jul 27. Thorac Cancer. 2019. PMID: 31350820 Free PMC article. Clinical Trial.
539 results